<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Baxter &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/baxter/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Mon, 17 Jul 2023 03:10:16 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>Baxter &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国七氟烷市场研究报告：2016-2019年CAGR达3.2%</title>
		<link>https://www.yuanzhezixun.com/report-on-chinese-sevoflurane-market/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Mon, 12 Apr 2021 09:14:26 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Maruishi Pharmaceutical Co.]]></category>
		<category><![CDATA[七氟烷]]></category>
		<category><![CDATA[七氟烷区域分析]]></category>
		<category><![CDATA[七氟烷市场份额]]></category>
		<category><![CDATA[七氟烷市场竞争]]></category>
		<category><![CDATA[七氟烷市场细分]]></category>
		<category><![CDATA[七氟烷市场规模]]></category>
		<category><![CDATA[上海恒瑞医药]]></category>
		<category><![CDATA[凯特力]]></category>
		<category><![CDATA[喜保福宁]]></category>
		<category><![CDATA[奇佛美]]></category>
		<category><![CDATA[河北一品制药]]></category>
		<category><![CDATA[益君宁]]></category>
		<category><![CDATA[鲁南贝特]]></category>
		<category><![CDATA[麻醉剂]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=23628</guid>

					<description><![CDATA[在中国市场七氟烷市场销售收入在2017-2019年逐年增长，2019年达7.24亿元。CRI元哲预计，随着疫情的好转，在2021-2025年，七氟烷会在中国的销售情况也会有恢复性的增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>全球重症肌无力市场研究报告预测至2023年</title>
		<link>https://www.yuanzhezixun.com/quanqiuzhongzhengjiwulishichangyanjiubaogaoyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Tue, 23 Apr 2019 06:33:55 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Alexion Pharmaceuticals]]></category>
		<category><![CDATA[and Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[CSL Behring]]></category>
		<category><![CDATA[GE Healthcare]]></category>
		<category><![CDATA[Grifols S.A.]]></category>
		<category><![CDATA[KONINKLIJKE PHILIPS N.V.]]></category>
		<category><![CDATA[Medtronic PLC]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Shire]]></category>
		<category><![CDATA[重症肌无力]]></category>
		<category><![CDATA[重症肌无力市场]]></category>
		<category><![CDATA[重症肌无力市场报告]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=19509</guid>

					<description><![CDATA[重症肌无力（MG）是一种免疫系统神经肌肉疾病，其主要作用是减少AChRs在肌肉终板膜上的会聚。北美和拉丁美洲共同致力于全球重症肌无力市场的发展。与此同时，欧洲和亚太地区在价值方面占据第二和第三位。最近重症肌无力的优势已经显着上升，这促使治疗要求急剧增加。预计全球重症肌无力市场在预计期间（2018-2023）的年增长率为9.61％。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>全球预填充注射器市场研究报告 &#8211; 预测到2024年：预计将达到8397.23百万美元，复合年增长率为10.20％</title>
		<link>https://www.yuanzhezixun.com/quanqiuyutianchongzhusheqishichangyanjiubaogao-yucedao2024nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Fri, 11 Jan 2019 02:53:24 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Dickinson and Company]]></category>
		<category><![CDATA[Gerresheimer AG]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[Nipro Corporation]]></category>
		<category><![CDATA[Prefilled Syringes]]></category>
		<category><![CDATA[SCHOTT AG]]></category>
		<category><![CDATA[Terumo Corporation]]></category>
		<category><![CDATA[Vetter Pharma International GmbH]]></category>
		<category><![CDATA[Weigao Group]]></category>
		<category><![CDATA[West Pharmaceutical]]></category>
		<category><![CDATA[注射器]]></category>
		<category><![CDATA[预充式注射器]]></category>
		<category><![CDATA[预装填注射器]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=16950</guid>

					<description><![CDATA[到2024年，全球预充式注射器市场预计将达到8397.23百万美元，复合年增长率为10.20％。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>2018年中国血液制品行业研究报告</title>
		<link>https://www.yuanzhezixun.com/2018nianzhongguoxueyezhipinxingyeyanjiubaogao/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Thu, 09 Aug 2018 06:19:17 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[CSL Behring]]></category>
		<category><![CDATA[Grifols]]></category>
		<category><![CDATA[Octapharma]]></category>
		<category><![CDATA[人免疫球蛋白类]]></category>
		<category><![CDATA[人福医药]]></category>
		<category><![CDATA[人血白蛋白]]></category>
		<category><![CDATA[凝血因子类]]></category>
		<category><![CDATA[天坛生物]]></category>
		<category><![CDATA[成都蓉生]]></category>
		<category><![CDATA[血浆]]></category>
		<category><![CDATA[血液制品]]></category>
		<category><![CDATA[重组人凝血因子Ⅷ]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=14471</guid>

					<description><![CDATA[据CRI估算，2017年，需要至少10000吨投浆量才能满足中国市场需求，而实际供给量仅为约7000吨，整个中国的年投浆量只有CSL Behring的约一半。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
